PranaX

About PranaX

PranaX is a regenerative biotechnology company founded by Dr. Steven J. Greco in 2022. The company is headquartered in Houston, Texas, at the Levit Green life science campus, a hub for health innovation. PranaX focuses on harnessing stem cell-derived exosomes to develop products and services for wellness, aiming to combat age-related decline. The company's name is inspired by the Sanskrit word 'Prana', signifying vital life energy, which reflects its mission to advance wellness through science-based innovation.

Dr. Steven J. Greco, the founder, serves as the Chief Strategy Officer and has over 20 years of experience in Stem Cell Biology. He established the company's corporate structure and business model. The leadership team also includes Phillip Maderia as CEO, who brings over 30 years of biopharmaceutical manufacturing experience, and Kenneth Klein as CFO. The company has scientific co-founders, Dr. Valerie S. Kalluri and Dr. Raghu Kalluri, who have personal financial relationships with PranaX disclosed to MD Anderson's Conflict of Interest Committee.

PranaX's business model is centered on a proprietary technology portfolio, which includes an exclusive license from The University of Texas MD Anderson Cancer Center. This license provides access to a core patent portfolio for exosome manufacturing, engineering, and non-cancer therapeutic applications. The technology is notable for being part of the first FDA-approved clinical study using mesenchymal stem cell-derived exosomes. PranaX operates its own FDA-registered, GMP-compliant manufacturing facility in Houston, which includes a 7,400-square-foot lab and a cGMP cleanroom suite. This allows for in-house quality assurance and scalable production. The company's first commercial product is ExoWELL™, a physician-directed, GMP stem cell exosome supplement for health and wellness applications. It also offers ExoSTORE™, a service for personal exosome banking. PranaX's business model is provider-first, partnering with clinics to deliver its exosome products and services.

The company has secured significant funding to support its growth, closing an oversubscribed Series A financing round of $17 million in January 2026. This funding is intended to advance research and development, expand infrastructure, support strategic partnerships, and accelerate product commercialization. PranaX aims to make a difference in improving individuals' health spans by developing products that can help reduce inflammation, improve cognitive function, and boost the immune system.